Stock Market News

The time for a Sarepta Therapeutics takeover is ‘ripe’ state analysts


The time for a Sarepta Therapeutics (SRPT) takeover is ‘ripe’ states analyst

 

SRPT
-0.15%

Add to/Remove from Watchlist

Add to Watchlist

Add Position

Position added successfully to:

Please name your holdings portfolio

Type:

BUY
SELL

Date:

 

Amount:

Price

Point Value:


Leverage:

1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000

Commission:


 

Create New Watchlist
Create

Create a new holdings portfolio
Add
Create

+ Add another position
Close

By Sam Boughedda 

Oppenheimer analysts said in a note Friday that Sarepta Therapeutics Sarepta Therapeutics Inc (NASDAQ:SRPT) is «ripe» for a takeover.

The analysts, who have an Outperform rating and a $150 price target on the stock, explained that while the M&A Buy thesis for Sarepta has been explained well, they believe the timing might be «more ripe currently.»

Sarepta Therapeutics shares are down 0.4% at the time of writing. However, they have climbed 27% so far in 2022.

Oppenheimer upgraded Sarepta in December last year, stating it had a «best-in-class rh74 AAV capsid.»

In today’s note, the analysts wrote: «The best-in-class safety profile for SRPT’s rh74 AAV vector is bolstered by the company’s leading manufacturing expertise in this area; possibly creating a significant moat around the muscular dystrophy programs. The LGMD programs and the RNA-based PPMO programs are underappreciated. We stay bullish.»

«The optics for a SRPT takeout are easy, in our view: (1) a leader in gene therapy, (2) a leader in muscular dystrophies (DMD, LGMDs), (3) a fairly diverse pipeline with RNA-targeted therapies and gene editing approaches also, and (4) a strong financial backdrop to achieve its objective to be a leader in genetic medicines in rare diseases. We add some nuance to these views,» they added.

Source

Похожие статьи

Добавить комментарий

Ваш адрес email не будет опубликован. Обязательные поля помечены *

Кнопка «Наверх»